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Introduction: Syndecans are heparan sulphate proteoglycans expressed by endothelial cells. Syndecan-3 is
expressed by synovial endothelial cells of rheumatoid arthritis (RA) patients where it binds chemokines, suggesting
a role in leukocyte trafficking. The objective of the current study was to examine the function of syndecan-3 in joint
inflammation by genetic deletion in mice and compare with other tissues.
Methods: Chemokine C-X-C ligand 1 (CXCL1) was injected in the joints of syndecan-3−/−and wild-type mice and
antigen-induced arthritis performed. For comparison chemokine was administered in the skin and cremaster muscle.
Intravital microscopy was performed in the cremaster muscle.
Results: Administration of CXCL1 in knee joints of syndecan-3−/−mice resulted in reduced neutrophil accumulation
compared to wild type. This was associated with diminished presence of CXCL1 at the luminal surface of synovial
endothelial cells where this chemokine clustered and bound to heparan sulphate. Furthermore, in the arthritis
model syndecan-3 deletion led to reduced joint swelling, leukocyte accumulation, cartilage degradation and
overall disease severity. Conversely, CXCL1 administration in the skin of syndecan-3 null mice provoked increased
neutrophil recruitment and was associated with elevated luminal expression of E-selectin by dermal endothelial
cells. Similarly in the cremaster, intravital microscopy showed increased numbers of leukocytes adhering and rolling
in venules in syndecan-3−/−mice in response to CXCL1 or tumour necrosis factor alpha.
Conclusions: This study shows a novel role for syndecan-3 in inflammation. In the joint it is selectively
pro-inflammatory, functioning in endothelial chemokine presentation and leukocyte recruitment and cartilage
damage in an RA model. Conversely, in skin and cremaster it is anti-inflammatory.Introduction
Syndecans (sdcs) are heparan sulphate proteoglycans
(HSPG) composed of a core protein to which heparan
sulphate (HS) glycosaminoglycan chains are covalently
attached. These molecules form part of the glycocalyx,
which comprises a network of membrane-bound proteo-
glycans and glycoproteins at the cell surface of endothe-
lial cells [1-3]. There are four mammalian syndecans,
designated syndecan-1 (sdc-1), -2, -3, and -4, which have* Correspondence: jim.middleton@bristol.ac.uk
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The variable ectodomain, which is exposed to the extra-
cellular environment, contains three to five HS and in
some cases chondroitin sulphate chains, and is attached to
the cell membrane via a hydrophobic transmembrane seg-
ment [6,7]. In addition, there is an intracellular domain
containing peptide sequences, which serve as substrates
for cellular kinases, enabling syndecans to act as signaling
molecules [8].
HSPGs have been shown to play a pro-inflammatory
role [9-11]. For example, on endothelial cells they bind
and present chemokines to blood leukocytes that leads to
leukocyte integrin activation, crawling on the endothelial
cell surface and extravasation [12-15]. This interaction
involves chemokine immobilisation and concentration atLtd. This is an Open Access article distributed under the terms of the Creative
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iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
Kehoe et al. Arthritis Research & Therapy 2014, 16:R148 Page 2 of 14
http://arthritis-research.com/content/16/4/R148the endothelial surface and stimulation of leukocyte mi-
gration into the tissue [16]. Evidence also suggests that HS
functions in chemokine transcytosis, which relays chemo-
kines from basal to luminal surfaces of endothelial cells
for their presentation to blood leukocytes [12,17-19]. Fur-
thermore, endothelial HS may act as an adhesion mol-
ecule, for example binding L-selectin during neutrophil
rolling [19]. In contrast, data also indicate that HSPGs
may be anti-inflammatory, for example in disease models
of nephritis and lung inflammation using sdc-1 and sdc-4
knockout mice [20-25]. Furthermore, removal of HS by
heparanase leads to increased leukocyte adhesion to the
cremaster endothelium by intravital microscopy, suggest-
ing an anti-inflammatory function [26]. Further work is
needed to address the apparent contradictory roles of
HSPGs in inflammation. Whether sdcs are pro- or anti-
inflammatory may relate to the particular tissue where
they are expressed or the inflammatory state.
Inflammation is a central feature of rheumatoid arthritis
(RA) that affects around 1% of the population and can re-
sult in disability and morbidity. In RA, inflammation of
the joint synovium is characterised by the infiltration and
activation of leukocytes, which can lead to progressive de-
struction of cartilage and bone. Chemokines are involved
in stimulating the infiltration of leukocytes into inflamed
tissue and there is substantial evidence showing an in-
volvement of these mediators and their receptors in RA
[27]. For example, chemokine C-X-C ligand 1 (CXCL1)
and CXCL8 are abundant in the sera, synovial fluid and
synovium in human RA [27-32]. They are produced by
synovial macrophages and other cells and attract neutro-
phils primarily. Furthermore, sdcs have been shown to be
expressed in arthritic joints and sdc-4 functions in joint
destruction [33-36].
A CXCL8 binding site on endothelial HSPG has been
demonstrated in the synovium of RA patients [33]. In
order to clarify which HSPG bound the chemokine,
immunolocalisation of syndecans and glypicans revealed
particularly strong expression of sdc-3 on RA synovial
endothelial cells with quantitative PCR confirming endo-
thelial expression. Furthermore anti-sdc-3 antibody and
heparanase reduced CXCL8 binding to the endothelium.
These data suggest a role for sdc-3 in synovial inflamma-
tion. Sdc-3 is the predominant syndecan in the nervous
system, where it was first identified, and has been associ-
ated with the control of feeding behaviour and the gener-
ation of cerebellar fibrillar plaques in Alzheimer’s disease
[37,38]. Sdc-3 is also an HSPG of the musculoskeletal sys-
tem. It has been found in the synovium in adult human
joints [33] and is expressed by chondrocytes [39,40]. In
addition, sdc-3 is involved in limb morphogenesis and
skeletal development and regeneration [41,42]. Several
studies have shown that it is expressed by endothelial cells
in the synovium, lymph nodes and liver [33,43,44].Nothing is currently known about the role of sdc-3 in
inflammation, unlike sdc-1 and -4 [20-25]. The expression
of a CXCL8 binding site on endothelial sdc-3 in human
RA suggests a role for this HSPG in inflammatory disease
[33] although in vivo studies are needed to substantiate
this hypothesis. The current study addresses this question,
whether genetic deletion of sdc-3 in mice alters leukocyte
trafficking in response to murine CXCL1. This chemokine
is the functional homologue to CXCL8, which is absent in
rodents. The study also addresses if deletion of sdc-3 alters
the severity and progression of disease in an RA model.
The involvement of sdc-3 in leukocyte recruitment in the
synovium was compared to that in the skin and cremaster
muscle. This was to find out if sdc can play a different role
in different tissues, which may help explain its apparent
contradictory function in inflammation. We show that
sdc-3 plays a dual role in inflammation depending on the
tissue and vascular bed. In the joint it is pro-inflammatory,
since its deletion leads to reduced leukocyte recruitment
and the severity of arthritis. However, in the skin and cre-
master it is anti-inflammatory, since its deletion leads to
enhanced leukocyte interaction with the endothelium and
recruitment. This is the first study to show a role for sdc-3
in inflammation and reveals its function is tissue-selective.
Methods
Animals
Experiments were undertaken in 7- to 10-week-old inbred
C57Bl/6 wild-type (sdc-3+/+) and sdc-3 null (sdc-3−/−)
mice. Sdc-3−/−mice were generated by Dr Ofer Reizes,
Cleveland, USA [37]; they are viable, fertile and develop
normally. Procedures were performed with ethical ap-
proval from the Home Office, UK, project licence PPL
40/3047.
Chemokine-driven leukocyte migration into the skin and
joints
Mice were injected intradermally or intra-articularly in
the knee joint space with recombinant murine CXCL1
(KC) (PeproTech, London, UK) 3 μg/site in phosphate-
buffered saline (PBS) [45]. PBS administration was used
as a control. After four hours, the animals were sacri-
ficed and skin biopsies or joints were processed for light
microscopy. Leukocyte recruitment into the dermis and
synovium was observed by light microscopy, neutrophils
being identified by their lobed nuclear morphology. To
quantitate leukocyte recruitment the number of neutro-
phils in the synovium was randomly counted in 10 fields
of view at x780 magnification per section from sdc-3−/−
(n = 8) and sdc-3+/+ (n = 8) mice.
Myeloperoxidase (MPO) assay
The MPO assay was used as a surrogate marker for the
presence of neutrophils in skin tissue and was carried
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mice were snap frozen in liquid nitrogen and homoge-
nized on ice in 500 μl of PBS with 0.01 M EDTA and a
proteinase inhibitor mix (Sigma-Aldrich, Poole, UK) and
1 ml of 1.5% Triton X-100 in PBS. Samples were placed
on a rotary shaker at 300 rpm on ice for 30 min, centri-
fuged at 12,000 × g for 10 min, and supernatants were
collected. Total protein concentration for each sample
was quantified by BCA Lowry assay (Thermo Scientific
Pierce, Cramlington, UK). The protein concentration in
all tissue extracts was adjusted to 0.9 mg/ml. MPO activ-
ity was determined by using the EnzChek MPO Activity
Assay Kit (Invitrogen, Paisley, UK) according to the manu-
facturer’s instructions.
Immunofluorescence
For CXCL1 (KC) and E-selectin detection in skin and
joint samples we used a tyramide signal amplification kit
[46] (Molecular Probes, Invitrogen). Briefly, formalin-
fixed, wax-embedded sections of skin and joints were
de-waxed, rehydrated, washed in PBS, and skin subjected
to antigen retrieval in Tris-HCl buffer, pH 9.0, at 100°C
in a water-bath for 20 min; for joints antigen retrieval
was in 10 mM Tris-HCl buffer, 1 mM EDTA and 0.05%
Tween 20, pH 9.0, overnight at 65°C. The endogenous
peroxidase was blocked by incubation for 10 min with
3% H2O2 followed by incubation with 1% blocking re-
agent for 60 min at room temperature. Sections were in-
cubated for 60 min with rabbit anti-murine CXCL1
polyclonal antibody (PeproTech) at 2 μg/ml or rat anti-
murine E-selectin monoclonal antibody at 5 μg/ml
(kindly supplied by Dr Alexander Zarbock, University of
Munster, Germany). Sections were then treated with
HRP-conjugated goat anti-rabbit or goat anti-rat second-
ary antibodies for 60 min, then Alexa Fluor™ 488 tyra-
mide for 10 min. For sdc immunofluorescence, sections
were treated with affinity purified rabbit anti-mouse sdc-
3 (1:500) [37] goat anti-rabbit Alexa 594 antibody (Invi-
trogen) containing 10% mouse serum. Tissue sections
were stained with DAPI for cell nuclei and analysed
using a Leica IX51 microscope (Leica, Wetzlar,
Germany). Control sections were negative when treated
with rabbit or rat immunoglobulin (Ig)G instead of pri-
mary antibodies (added at the same concentrations) or
when the primary antibodies were omitted.
For dual labelling, sections were treated with anti-E-
selectin (as above) together with rabbit anti-von Willeb-
rand factor (1:100; Dako, Ely, UK) followed by goat
anti-rabbit Alexa 594 second antibody (Invitrogen) For
quantitation of E-selectin expression, five vessels were
randomly sampled per section of synovium (n = 6 sdc-3
null and wild-type mice with antigen-induced arthritis
(AIA) at day 3) and skin (n = 8 sdc-3 null and wild-type
mice). The numbers of vessels showing a luminal E-selectindistribution were counted. For quantitation of CXCL1
on endothelial cells five vessels were randomly sampled
per skin (n = 8 sdc-3+/+and n = 9 sdc-3−/−mice) and
joint (n = 6 sdc-3+/+and sdc-3−/−mice) section.
Heparanase treatment of sections was performed using
a previously described method [33]. Briefly, formalin-
fixed, wax-embedded sections of CXCL1-injected joints
were de-waxed, rehydrated, washed in PBS, and sub-
jected to antigen retrieval as above. The sections were
treated with 20 units/ml of heparanase I and 4 units/ml
heparanase III (both Sigma-Aldrich, UK) in HBSS, or
HBSS alone, for 1.5 hours at 37°C. After enzymatic treat-
ment, the samples were rinsed twice with HBSS before
CXCL1 immunolocalisation as described above.Intravital microscopy
The effects of sdc-3−/−on leukocyte rolling and stationary
adhesion was also measured in vivo in the cremaster
muscle microcirculation using intravital microscopy (PPL
40/2747) [47]. Briefly, in anaesthetized (ketamine/xylazine;
intraperitoneally (ip)) mice, the testis was exposed through
a small scrotal incision and the cremaster muscle exter-
iorised, cleared of connective tissue and pinned across a
glass coverslip on a specialised microscope stage. The
muscle was continuously superfused with bicarbonate-
buffered saline (131.7 mM NaCl, 4.69 mM KCl, 2.7 mM
CaCl2, 2.1 mM MgCl2 and 14.44 mM NaHCO3, pH 7.4),
equilibrated with 5% CO2 in N2 and maintained at 37°C.
Prior to intravital observations, mice were either pre-
treated with an intrascrotal injection of TNFα (500 ng in
200 μl; R&D Systems, Abingdon, UK) for three hours or
the cremaster was superfused with CXCL1 (5nM in
500 ml; Peprotech) for 1 hour. Control mice received a
PBS vehicle. Leukocyte-endothelial cell interactions were
observed in single unbranched post-capillary venules
(PCV; 20 to 50 μm diameter). Leukocyte rolling was de-
termined by counting numbers of cells rolling along a
100 μm PCV segment within 60 seconds. A leukocyte
was considered firmly adherent if it remained stationary
for ≥30 seconds.Induction of murine antigen-induced arthritis (AIA)
Experiments were performed in 7- to 8-week-old male
mice. Murine AIA was induced as described [48]. Briefly,
mice were immunised subcutaneously with 1 mg/ml of
methylated bovine serum albumin (mBSA) emulsified
with an equal volume of Freund’s complete adjuvant and
injected intraperitoneally with 100 μl heat-inactivated Bor-
detella pertussis toxin (all reagents from Sigma-Aldrich).
The immune response was boosted one week later.
Twenty-one days after the initial immunisation, murine
AIA was induced by intra-articular injection of 10 mg/ml
mBSA in PBS in the right knee (stifle) joint. For a control,
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joint.
Animals were inspected daily for arthritis development
by measuring knee joint diameters using a digital microm-
eter. The difference in joint diameter between the arthritic
(right) and non-arthritic control (left) in each animal gave
a quantitative measure of swelling (in mm).
Histological assessment
Animals were killed at the indicated times after induc-
tion of arthritis. Joints were fixed in neutral buffered for-
mal saline, and decalcified with formic acid at 4°C before
embedding in paraffin. Mid-sagittal serial sections (7 μm
thickness) were cut and stained with haematoxylin and
eosin (H&E). Two independent observers blinded to the
experimental groups scored sections. Synovial hyperplasia,
cellular exudate and cartilage depletion were scored from
0 (normal) to 3 (severe); synovial infiltrate was scored
from 0 to 5 [48,49]. Cartilage damage was scored on serial
haematoxylin/safranin O-stained sections. All parameters
were subsequently summed to give an arthritis index
(mean ± SEM).
Statistics
Differences between groups were compared by Mann-
Whitney U or unpaired t tests, with P <0.05 being deemed
as significant.
Results
Sdc-3 deletion reduces neutrophil recruitment in
CXCL1-injected joints
To examine the effects of sdc-3 on inflammation we first
studied chemokine-driven leukocyte migration into the
knee joint. Intra-articular injection of murine CXCL1
stimulated the influx of neutrophils into the synovium of
the joints of sdc-3−/−and wild-type mice (Figure 1A),
whereas PBS-injected controls were negative for neutro-
phils. To compare and quantitate leukocyte recruitment
the number of migrated neutrophils in the synovia was
counted. A significant decrease (P <0.0001; t test) in the
number of neutrophils recruited in sdc-3−/−mice was
observed compared to wild type after CXCL1 injection
(Figure 1B). In PBS-injected controls there was no neutro-
phil recruitment in synovia of sdc-3−/−and sdc-3+/+mice.
Reduced chemokine presentation by synovial endothelial
cells in sdc-3−/−mice
Experiments were performed to examine if murine syn-
ovial endothelial cells expressed sdc-3, similar to human
synovial endothelial cells [33]. Immunoreactive sdc-3 was
demonstrated in blood vessels in normal and AIA synovia
of wild-type mice but not in sdc-3 null mice as control
(Figure 1C-F). Further controls in the absence of sdc-3
antibody (Figure 1G and H), or when substituted withrabbit control Ig, were also negative. Chemokines may be
produced extravascularly and a transcytosis mechanism
allows for these chemokines to be transported to the
luminal surface of the endothelium [12,45,50]. At this
interface HS is then involved in presenting the bound che-
mokines to signalling receptors on the surface of blood
leukocytes [51]. We wanted to test if deletion of sdc-3
would alter chemokine binding and presentation at the
endothelial surface, which may explain the reduced neu-
trophil recruitment in sdc-3 null mice in response to
CXCL1 (Figure 1B). Sections of the same CXCL1-injected
joints of wild type (n = 8) and sdc-3−/− (n = 9) mice as
used in Figure 1 were immunostained with a CXCL1 anti-
body using tyramide amplification and observed by con-
focal immunofluorescence. CXCL1 appeared as discrete
clusters associated with synovial endothelial cells of sdc-3
null and wild-type joints (Figure 2A and B). In PBS-
injected control joints there were no CXCL1 clusters in
synovial endothelial cells of knockout and wild-type mice
(Figure 2C). Quantification revealed a three-fold reduction
in the numbers of endothelial CXCL1 clusters per blood
vessel in sdc-3−/−compared to sdc-3+/+joints (P = 0.0003;
t test) (Figure 2F). These data were further separated into
luminal or intracellular/abluminal distribution of endo-
thelial CXCL1. The numbers of luminal CXCL1 clusters
were reduced 6-fold in sdc-3−/−mice compared to wild
type (P = 0.0002; t test) (Figure 2G). However, there was
no significant difference comparing intracellular/ablum-
inal numbers of CXCL1 clusters in sdc-3 null and wild-
type mice (Figure 2G).
Serial sections of CXCL1-injected joints were treated
with heparanase I and III to degrade heparan sulphate
prior to CXCL1 immunolocalisation. Use of these en-
zymes resulted in lack of CXCL1 immunofluorescence in
endothelial cells of wild-type and sdc-3−/−synovial blood
vessels (Figure 2D). Quantitation revealed that for wild
type the mean number of endothelial CXCL1 clusters
per blood vessel after heparanase digestion was 2.8 ± 0.7
(mean ± SE, n = 6), which was significantly lower than
without heparanase (28.7 ± 3.2, see Figure 2F) (P <0.0001;
t test). For sdc-3 null mice the mean number of endothe-
lial CXCL1 clusters per blood vessel after heparanase was
2.7 ± 1.8 and 8.7 ± 1.8 without heparanase (both mean ±
SE, n = 5) (Figure 2F) and these values did not sig-
nificantly differ. These heparanase data suggest that
the heparan sulphate chains of endothelial sdc-3 bind
CXCL1 clusters. Controls in the absence of anti-CXCL1
were negative (Figure 2E). Sections were also immuno-
stained for E-selectin. Although E-selectin was detected
in synovial endothelial cells, it was less abundant than
in skin endothelial cells, and there was no significant
difference in E-selectin distribution between sdc-3−/−and
sdc-3+/+mice in the presence or absence of CXCL1 (data
not shown).
Figure 1 Sdc-3 deletion reduces neutrophil recruitment in CXCL1-injected joints. Sdc-3 null and wild-type mice were injected intra-articularly
with 3 μg per knee joint of recombinant murine CXCL1 or PBS and after 4 hours processed for histology. (A) Haematoxylin and eosin staining
reveals neutrophil recruitment in the synovium following CXCL1 administration with PBS injected as control; insets show detail of synovium.
Results are shown from a wild-type joint. Scale bar 500 μm (for inserts 50 μm). (B) Decrease in the number of recruited neutrophils in
sdc-3−/−mice compared to wild-type animals following CXCL1 administration. Data are means ± SEM, n = 8 mice per treatment. ***P <0.0001
comparing CXCL1-injected joints. (C) Sdc-3 immunolocalises to the blood vessel in synovium of wild-type mice. (D) is the same image as (C)
stained for DAPI to show cell nuclei. (E) absent staining for sdc-3 in a blood vessel in sdc-3 −/−synovium. (F) is the same image as (E) stained
for DAPI to show cell nuclei. (G) is a negative control of the synovium of wild-type mouse in the absence of sdc-3 antibody and (H) is the same
area stained for DAPI to show the presence of blood vessels. Bar =120 μm in C to H. CXCL1, chemokine C-X-C ligand 1; DAPI, 4',6-diamidino-2-
phenylindole; PBS, phosphate-buffered saline.
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Since the above data suggested that sdc-3 is pro-
inflammatory in the joint the role of this HSPG in a model
of inflammatory disease, namely RA, was assessed. AIA
was induced in the knee joints of sdc-3−/−and wild-type
mice and joint swelling, synovial inflammation and car-
tilage destruction were measured. Knee joint diameter
(swelling), a clinical indication of joint inflammation,was significantly less in sdc-3−/−mice compared to wild
type 24 hours after arthritis induction (0.63 ± 0.06 mm
versus 0.96 ± 0.05 mm; P <0.0001 ANOVA and Tukey
post tests) (Figure 3A). This difference continued for
approximately seven days post-intra-articular mBSA ad-
ministration (P <0.001).
Histologically, AIA was characterised by synovial hyper-
plasia of the synovial lining layer, infiltration of the
Figure 2 (See legend on next page.)
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Figure 2 Reduced chemokine presentation by synovial endothelial cells in sdc-3−/−mice. In the same samples as in Figure 1 sections of
CXCL1-injected joints of wild-type and sdc-3−/−mice were stained with a CXCL1 antibody using tyramide amplification, and DAPI, and viewed
by immunofluorescence. (A and B) Synovial endothelial cells of wild-type mouse joint; CXCL1 occurs as clusters with white arrows showing
examples of luminal chemokine and red arrows intracellular or abluminal chemokine. The endothelial cell layer is labelled (e) and the lumen of
the blood vessel (L) containing red blood cells. (C) No CXCL1 clusters are present in the endothelial cells of PBS-injected controls (arrows); this
image is from a wild-type mouse. (D) There are less CXCL1 clusters in endothelial cells of following treatment with heparanase I and III to degrade
heparan sulphate prior to immunostaining. (E) is a negative control of the synovium of wild-type mouse in the absence of CXCL1 antibody.
Bar = 30 μm in A to E. (F) Quantification of CXCL1 staining shows decrease in the numbers of endothelial CXCL1 clusters per blood vessel in
sdc-3−/− (n = 6) compared to wild-type (n = 6) joints. Data are mean ± SEM. ***P = 0.0003. (G) shows the data in (F) expressed as number of
CXCL1 clusters at the luminal surface or intracellularly/abluminally in synovial endothelial cells. There is a reduction of the numbers of luminal
CXCL1 clusters in sdc-3−/−mice compared to wild type, ***P = 0.0002. Data are means ± SEM. CXCL1, chemokine C-X-C ligand 1; DAPI, 4',6-diami-
dino-2-phenylindole; PBS, phosphate-buffered saline.
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ity, and loss of proteoglycan from the articular cartilage, as
observed in haematoxylin/eosin and haematoxylin/safra-
nin-O stained sections (Figure 3B and D). These changes
did not occur in contralateral knee joints, which were
injected with PBS instead of mBSA and appeared histolog-
ically normal. The degree of leukocyte infiltration and car-
tilage destruction (proteoglycan loss) appeared less severe
in sdc-3 null mice compared to wild type (Figure 3B ver-
sus C, D versus E). In order to quantitate these changes,
parameters were scored as a measure of disease severity
and differences between sdc-3 null and wild-type mice
were apparent (Table 1). There was a significant reduction
of synovial leukocyte infiltrate comprising mainly neutro-
phils (P <0.01), cartilage depletion (P <0.05) and arthritic
index representing overall disease severity (P <0.01) in
sdc-3−/−compared to sdc-3+/+mice at day 3 (Table 1) (all
comparisons Mann-Whitney test). At day 14 and 21 post
intra-articular injection of mBSA, there were no signifi-
cant differences between wild type and sdc-3−/−for all pa-
rameters except exudate, which was significantly reduced
in sdc-3 null mice (P <0.02 Mann-Whitney test) at day 21.
In addition, the infiltrate was less in sdc-3−/−mice com-
pared to sdc-3+/+although this approached significance at
day 21 (P = 0.06 Mann-Whitney test).
Sdc-3 deletion provokes enhanced neutrophil recruitment
in CXCL1-injected skin
In order to compare the inflammatory role of sdc-3 in the
joint with other tissues, skin was injected intradermally
with murine CXCL1 or PBS as control (as Figure 1). Four
hours after CXCL1 injection, histological staining revealed
an influx of leukocytes into the dermis in sdc-3 null and
wild-type mice (Figure 4A). These leukocytes were identi-
fied histologically as being neutrophils. To quantitate dif-
ferences in neutrophil recruitment, we examined MPO
activity as a marker for the presence of these cells in skin
extracts. There was an increase in MPO levels following
CXCL1 injection compared to PBS in sdc-3 null (P <0.005;
t test) and wild-type (P <0.005; t test) mice (Figure 4B).Interestingly, a significant 30% increase (P <0.03; t test)
in MPO activity over wild type was observed in
sdc-3−/−mice after CXCL1 administration (Figure 4B).
Baseline activity of MPO in PBS-injected control sam-
ples did not significantly differ between sdc-3 null and
wild-type mice.
Immunofluorescence using anti-murine sdc-3 showed
that this HSPG was expressed in the endothelium of the
dermis in wild-type mice (Figure 4C and D). To further
investigate the potential mechanism of increased neutro-
phil recruitment after CXCL1 challenge adhesion molecule
expression was examined. E-selectin immunolocalisation
was performed in skin tissue sections (Figure 4E and F).
This adhesion molecule is expressed by dermal endothelial
cells and is involved in the rolling stage of leukocyte ad-
hesion to the endothelium [52-55]. Using dual labelling
E-selectin co-localised with von Willebrand factor as a
marker of endothelial cells (Additional file 1C to E), and
the proportion of von Willebrand factor positive dermal
blood vessels that expressed E-selectin was >95% (n >15
vessels per wild-type and sdc-3−/−mouse). E-selectin ex-
hibited a predominantly luminal or intracellular distribu-
tion in the endothelial cells of the dermis in sdc-3−/−and
sdc-3+/+mice (Figure 4E and F; Additional file 1A and B).
Quantification revealed that there was a two-fold increase
in the numbers of vessels with a luminal E-selectin distri-
bution in sdc-3−/−mice compared to wild type (P <0.008
Mann-Whitney test) following CXCL1 administration
(Figure 4G). When PBS was administered instead of
CXCL1, as vehicle-injected control, there was also signifi-
cantly more vessels with a luminal E-selectin distribution
in sdc-3 null mice compared to wild type (Figure 4G). In
sdc-3−/−mice there was no significant difference in lu-
minal E-selectin between CXCL1- and PBS-injected skin
(Figure 4G), suggesting that this chemokine was not af-
fecting E-selectin distribution. After injection of CXCL1,
this chemokine could be detected as a uniform distribu-
tion in endothelial cells of dermal venules by immuno-
fluorescence, however, there was no significant difference
in the number or percentage of these cells positive for
Figure 3 Antigen-induced arthritis in sdc-3−/−and wild-type mice. Arthritis was induced by intra-articular injection of methylated BSA in the
right knee (stifle) joint. For a control, PBS was injected into the left knee joint. (A) Joint swelling after arthritis induction at t = 0, n ≥16 sdc-3+/+and
sdc-3−/−mice per time point. Data are means ± SEM for right knee after subtraction of left knee control. ***P <0.001 comparing sdc-3−/−and sdc-3+/+mice
at the time points indicated. (B-E) Synovial inflammation and cartilage destruction in mouse antigen-induced arthritis three days after induction.
B, wild-type knee joint with marked leukocyte infiltration of the synovium (*), mainly neutrophils. D, wild-type knee joint with loss of proteoglycan
staining in the surface regions of tibial and femoral articular cartilage. C and E show sdc-3−/−knee joints and lack of leukocyte infiltration (*) in the
synovium and degradation of articular cartilage. B and C were stained with haematoxylin and eosin and D and E with haematoxylin and safranin-O.
Scale bar =160 μm in B to E. BSA, bovine serum albumin; PBS phosphate-buffered saline.
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(data not shown); this suggests that CXCL1 presentation
in skin may be occurring by a different proteoglycan
than sdc-3. Control sections treated in the absence of
E-selectin, von Willebrand or CXCL1 antibodies were
negative.Increased rolling and adhesion of leukocytes in cremaster
venules in sdc-3 null mice
Intravital microscopy was used to examine the effects of
sdc-3 gene deletion on the rolling and firm adhesion of
leukocytes to venular endothelial cells in the cremaster
muscle. The basal number of rolling leukocytes was not
Table 1 Joint inflammation and cartilage damage on day 3 of antigen-induced arthritis
Species Hyperplasia Synovial infiltrate Exudate Cartilage depletion Arthritis index
Syndecan 3−/− 2.07 ± 0.23 2.67 ± 0.67** 0.63 ± 0.24 0.63 ± 0.24* 6.00 ± 0.75**
Syndecan-3+/+ 2.57 ± 0.15 3.97 ± 0.24 1.40 ± 0.31 1.40 ± 0.27 9.33 ± 0.74
Synovial hyperplasia of the lining layer, synovial infiltration of the sublining by leukocytes, exudate in the joint cavity, and loss of proteoglycan from the articular
cartilage were observed in haematoxylin/eosin and haematoxylin/safrinin-O-stained sections. Sections were scored blind by two independent observers from 0 to
3 (hyperplasia, exudate and cartilage depletion) or 0 to 5 (infiltrate). The arthritis index is the sum of all observations. *P <0.05 and **P <0.01 of the parameter
compared to wild-type mice using Mann-Whitney U test.
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sdc-3−/−mice and wild-type mice (Figure 5A). Although
TNFα stimulation increased leukocyte rolling in wild-type
mice, this did not reach significance. However, a signifi-
cant increase in rolling was observed in TNFα-stimulated
sdc-3−/−mice when compared to either unstimulated sdc-
3−/− (P <0.01) or TNFα-stimulated wild-type (P <0.05)
mice (Figure 5A). Indeed, when compared to unstimulated
sdc-3−/−, an almost four-fold increase in rolling was ob-
served. Similarly, CXCL1 stimulation did not increase
leukocyte rolling in wild-type mice, but it was associated
with a significant increase in rolling in sdc-3−/−mice
when compared to unstimulated sdc-3−/− (P <0.01) or
CXCL1-stimulated wild-type (P <0.05) mice (Figure 5A).
Interestingly, the basal number of adherent leukocytes
was significantly (P <0.05) increased in unstimulated
sdc-3−/−mice when compared to wild-type mice, with
more than double the numbers of adherent cells ob-
served (Figure 5B). As expected, TNFα stimulation sig-
nificantly (P <0.05) increased leukocyte adhesion in
wild-type mice when compared to unstimulated wild-
type mice. However, this effect was more dramatic in
the sdc-3−/−mice, with significantly increased leukocyte
adhesion observed when compared to either unstimu-
lated sdc-3−/− (P <0.05) or TNFα-stimulated wild-type
(P <0.05) mice (Figure 5B). Indeed, when compared to un-
stimulated sdc-3−/−, a 2.2-fold increase in adhesion was
observed. Although CXCL1 stimulation did not increase
leukocyte adhesion in wild-type mice, it was associated
with a significant increase in adhesion in sdc-3−/−mice
when compared to CXCL1-stimulated wild type (P <0.05).
This did not reach significance when compared to un-
stimulated sdc-3−/−, presumably reflecting increased basal
adhesion in the sdc-3−/− (Figure 5B). All statistical com-
parisons for intravital microscopy were made by ANOVA
followed by Tukey’s pairwise tests.
Discussion
The current study demonstrated that sdc-3 played a role
in inflammation, but interestingly, highlighted both pro-
and anti-inflammatory properties for this proteoglycan
depending upon the tissue and nature of the inflamma-
tory insult. In the joint, chemokine administration re-
sulted in reduced neutrophil influx in the synovium of
sdc-3 null mice indicating that this HSPG is playing apro-inflammatory role. This effect may be attributed to
chemokine presentation by sdc-3 on synovial endothelial
cells since deletion of this HSPG reduced the presence
of chemokine CXCL1 on these cells. Furthermore, hepara-
nase reduced the amount of endothelial CXCL1 suggest-
ing the involvement of HS chains in binding CXCL1. The
chemokine in synovial endothelial cells was not uniformly
distributed but appeared to be bound to sdc-3 in clusters.
Thus CXCL1 may be concentrated and immobilised into
clusters at the endothelial surface for presentation to
blood leukocytes. This is in agreement with Hardy et al.
[15] who found a focal distribution of CCL2 bound to HS
at the apical endothelial surface during leukocyte transen-
dothelial migration in vitro. CXCL1 clusters were particu-
larly reduced at the endothelial surface in sdc-3−/−mice
whereas in the remainder of the cell in intracellular/
abluminal locations this was not the case. This suggests
that sdc-3 may be particularly involved in chemokine
presentation whereas other molecules may play a more
dominant role in transcytosis, such as the Duffy antigen/
receptor for chemokines [45,56]. The finding of sdc-3
binding and presenting CXCL1 in the current study is in
agreement with our previous study [33]. In human RA
there is induction of a CXCL8 binding site on sdc-3 HS
chains of synovial endothelial cells. Mice lack CXCL8 and
CXCL1 is the functional equivalent in the murine system.
Therefore taken together, these two studies suggest that
sdc-3 may be involved in binding CXC chemokines and
stimulating leukocyte trafficking into the RA synovium.
A pro-inflammatory function of sdc-3 was also appar-
ent in a murine model of RA. Induction of AIA in the
knee joint resulted in reduced joint swelling in sdc-3
knockout mice suggesting that sdc-3 contributes to the
clinical manifestation of the disease. This HSPG is also
involved in underlying inflammatory changes such as
leukocyte accumulation into the synovium, which was re-
duced in sdc-3 null mice as was the overall histological se-
verity of disease. The pro-inflammatory function of sdc-3
in AIA may be due to chemokine presentation by synovial
endothelial cells. Furthermore a role for sdc-3 in joint
damage, which is a major feature of RA, is implicated as
shown by the inhibitory effects of sdc-3 deletion on cartil-
age damage. This involvement of sdc-3 in cartilage dam-
age may be related to its pro-inflammatory function in the
synovium, via leukocyte recruitment leading to cytokine
Figure 4 Leukocyte migration after intradermal injection of CXCL1 in sdc-3 null and wild-type mice and altered distribution of
E-selectin. (A) Mice were injected intradermally with recombinant murine CXCL1 (3 μg/site in PBS) or PBS as control. After four hours the animals
were sacrificed and skin biopsies were processed for light microscopy. Haematoxylin and eosin staining of skin sections show neutrophil recruitment
into the dermis in sdc-3−/− (mid panel) and sdc-3+/+ (right panel) mice. The left micrograph shows skin from an sdc-3−/−mouse following PBS
administration. Scale bar 50 μm. (B) Using the same samples as in (A) lysates were prepared from skin biopsies and myeloperoxidase (MPO) activity
measured as a marker for the presence of neutrophils. Increased MPO activity is observed in sdc-3−/−compared to sdc-3+/+skin tissue. For sdc-3−/−mice
n = 9 with CXCL1 and with PBS, and for sdc-3+/+mice n = 10 with CXCL1 and with PBS. Data are means ± SEM. *P <0.03 compared with CXCL1
injected sdc-3+/+mice. #P <0.005 compared to respective PBS control. (C and D) Sdc-3 staining of endothelial cells is shown in a dermal
venule from a wild-type mouse. (E and F) E-selectin shows a luminal distribution in the endothelial cells of the dermis after PBS (E) and CXCL1
(F) administration, this section is from a sdc-3−/−mouse. Scale bar 50 μm for E-selectin and 25 μm for sdc-3 micrographs. (G) Quantification of
the number of blood vessels with a luminal E-selectin distribution in the dermis of sdc-3+/+ (n = 8) compared to sdc-3−/− (n = 9) mice. Data are
mean ± SEM, **P <0.008 compared to sdc-3 wild-type mice. CXCL1, chemokine C-X-C ligand 1; PBS, phosphate-buffered saline.
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of sdc-3 in the arthritis model may be mediated, at least in
part, by cells other than endothelial cells, since sdc-3 is
also expressed by chondrocytes [39,40]. Further studies in-
volving conditional deletion of sdc-3 in selected cell typesand examining the effect on arthritis severity would be of
interest in this respect.
Recent data suggest a role for sdc-4 in inflammatory
arthritis [34,35]. Using the human TNF transgenic
mouse model (hTNFtg) of RA, sdc-4 was involved in the
Figure 5 Increased rolling and adhesion of leukocytes in cremaster muscle post-capillary venules (PCV) in sdc-3 null mice by intravital
microscopy. (A) Significant increases in leukocyte rolling are observed in TNFα-stimulated sdc-3−/−mice when compared to either TNFα-stimulated
wild-type (WT) or unstimulated syn-3−/−mice. Similarly, CXCL1 stimulation induces greater rolling in sdc-3−/−mice. (B) Similar increases in leukocyte
adhesion are observed in TNFα- and CXCL1-stimulated sdc-3−/−mice. Data are means ± SEM, n = 3 to 6 mice per treatment. *P <0.05; **P <0.01. CXCL1,
chemokine C-X-C ligand 1; TNFα, tumour necrosis factor alpha.
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tilage, contributing to cartilage destruction. Sdc-4 also
regulates ADAMTS-5 activation and cartilage break-
down [36]. This suggests that sdcs may be involved in
various aspects of joint inflammation and damage in arth-
ritis, with endothelial sdc-3 functioning in leukocyte re-
cruitment and fibroblast sdc-4 in cartilage destruction.
Deletion of sdc-3 in the skin had the opposite effect
compared to that in the joint. When CXCL1 was injected
into the skin neutrophil recruitment was enhanced in sdc-
3−/−mice compared to wild type suggesting that this
HSPG plays an anti-inflammatory function in this tissue.
The effect may be mediated, at least in part, by theadhesion molecule E-selectin since the luminal distribu-
tion of E-selectin increased in knockout animals suggest-
ing increased expression of this adhesion molecule at the
endothelial surface. This may lead to elevated neutrophil
recruitment in the presence of CXCL1. E-selectin is
expressed in normal skin venules where it is upregulated
in skin inflammation [52-55]. Sdc-3 is part of the glycoca-
lyx, which can form an anti-adhesive layer to blood leuko-
cytes at the endothelial surface and it has been proposed
that this may mask endothelial adhesion molecules inhi-
biting leukocyte-endothelial interactions [1,10]. Steric hin-
drance may play a role in this process since the glycocalyx
can reach microns in thickness whereas selectins only
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fore loss of sdc-3 in knockout mice may lead to the
unmasking or altered expression of E-selectin at the lu-
minal endothelial surface leading to increased leukocyte
recruitment. This is in agreement with other studies that
show that stimuli that degrade the glycocalyx or induce a
more open mesh such as enzymes, cytokines, or ischaemia
and reperfusion appear to uncover adhesion molecules,
thereby allowing leukocytes to interact with the endothe-
lium [1-3,26]. For example, heparanase, which is a gly-
cosidase that removes HS, causes increased leukocyte
adherence at the endothelial surface in the cremaster ve-
nules of mice by intravital microscopy [26]. In the present
study, endothelial sdc-3 does not appear to be presenting
the chemokine CXCL1 in the skin since there was no dif-
ference in the presence of this chemokine on dermal ve-
nules in wild-type and knockout mice and other HSPGs
may be more involved in this mechanism. Thus in the skin
sdc-3 may be involved in regulating leukocyte adhesion
via altering the distribution or expression of the adhesion
molecule E-selectin.
Since the data obtained from the skin demonstrated
an anti-inflammatory role for sdc-3, we further investi-
gated its role using the more direct approach of intravi-
tal microscopy, which allowed real-time dynamic images
of leukocyte adhesion to be monitored in anaesthetised
mice in vivo. Furthermore, the effects on sdc-3 deletion
on leukocyte rolling could also be assessed, which was not
possible on static sections. Increased numbers of rolling
and adherent leukocytes in the venules of sdc-3−/−mice
in response to either CXCL1 or TNFα was observed com-
pared to wild type. These results suggest that sdc-3 has an
inhibitory effect on leukocyte-endothelial interactions in
response to inflammatory stimuli and are in accord with
those in skin. Intravital microscopy has been performed
in sdc-1 null mice following TNFα treatment where
there is increased adhesion of leukocytes to endothelial
cells of the mesentery venules [11,58]. These intravital
data, together with ours, indicate that sdc-3 and sdc-1
play similar roles in cremaster and mesenteric venules
using similar inflammation models. In these tissues sdc-3
and sdc-1 appear to be negative regulators of leukocyte-
endothelial interactions.
The anti-inflammatory role of sdc-3 in our models in
skin and cremaster is similar to that of sdc-1 and -4 in in-
flammatory disease models. Sdc-1 gene deletion in mice
reduces inflammation in models of allergic contact derma-
titis, allergic lung disease, colitis and nephritis, with in-
creased leukocyte recruitment and more severe disease
[20,21,23,24]. Similarly sdc-4 null mice exhibit increased
inflammation and neutrophil recruitment in a model of
pulmonary inflammation and lung injury [25]. Thus our
finding of sdc-3 having a pro-inflammatory role in syno-
vium in a mouse model of RA is more unusual amongstthe different sdc knockout models. Whether these HSPGs
have pro- or anti-inflammatory functions may depend on
the sdc, the tissue or cell-type where they are expressed
and/or the type of inflammation. Furthermore, specific
targeting of sdcs tailored to particular inflammatory dis-
eases is called for if they are to be exploited therapeutically
in human diseases. For example, blocking sdc-3 or sdc-4
in human RA would be of potential interest in reducing
inflammation and joint destruction, whereas this strategy
may have opposite effects in certain inflammatory condi-
tions of the skin, lung, gut and kidney.
In the current study, sdc-3 was found to be expressed
by endothelial cells in murine synovium and skin. This is
in agreement with human tissues where endothelial sdc-3
was found particularly expressed in the endothelial cells of
RA synovium [33]. Interestingly, sdc-3 is also found in
lymphoid tissue, where this HSPG perfectly delineates
some of the high endothelial venules [44]. These venules
are the preferred sites of lymphocyte extravasation which,
taken with the findings of the current study, suggests a
role for this HSPGs in lymphocyte trafficking in the lymph
nodes. Sdc-3 is also expressed by the endothelial cells in
human liver [43].Conclusions
Sdc-3 appears to have a tissue-selective role in inflam-
mation being pro-inflammatory in the joint, which may
be mediated by endothelial chemokine presentation. It is
also involved in leukocyte accumulation and cartilage dam-
age in joints with AIA. In the skin and cremaster it may be
anti-inflammatory, contributing to the anti-adhesive prop-
erties of the endothelial glycocalyx. This study helps clarify
the contradictory roles of HSPGs being reported as pro-
and anti-inflammatory and suggests the importance of
tissue-dependent functions of endothelial cells in the
case of sdc-3. Furthermore, it suggests that targeting
sdc-3 in the joint in inflammatory arthritis would be a
therapeutic strategy.Additional file
Additional file 1: E-selectin expression in mouse dermal endothelial
cells. Sections were treated with anti-murine E-selectin and von
Willebrand factor antibodies. E-selectin exhibits predominantly luminal
(A) or intracellular (B) distribution in wild-type mouse skin. (C) shows
E-selectin and (D) von Willebrand localisation as a marker of endothelial
cells from a sdc-3 −/−mouse, (E) is a merge of C and D. Cell nuclei are
blue using DAPI stain. Bar = 20 μm.Abbreviations
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